Recent advances in diagnostic technology

Applications in autoimmune and infectious diseases

Ajit Lalvani, Pier Luigi Meroni, Kerry A. Millington, Maria Luisa Modolo, Mario Plebani, Angela Tincani, Danilo Villalta, Andrea Doria, Anna Ghirardello

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Biomarkers are used ubiquitously as indicators of biological health. The development of genomic and proteomic multiplex technologies have enormously amplified biomarker discovery and application to diagnostic and therapeutic decisions in clinical practice. New technologies are now available that simultaneously identify a wide spectrum of biomarkers and save time and costs. Multiplexed assays can be coupled to other disease specific indicators (i.e., cytokines, single nucleotide polymorphisms) in order to get more powerful information. However, there is an urgent need for validation/standardization of the new assays before they are adopted into clinical diagnostics. It is worthy to note a new assay, T cell interferon gamma release (TIGRAs), which has recently been introduced in the diagnosis of latent tuberculosis infection. It seems to perform better than tuberculin skin test in patients with inflammatory rheumatic diseases. In this review, we focus on advantages and limits of novel approaches to the detection of autoantibody profiles in autoimmune diseases or pathogen signatures in microbiology.

Original languageEnglish
JournalClinical and Experimental Rheumatology
Volume26
Issue number1 SUPPL. 48
Publication statusPublished - 2008

Fingerprint

Autoimmune Diseases
Communicable Diseases
Biomarkers
Technology
Latent Tuberculosis
Tuberculin Test
Microbiology
Skin Tests
Rheumatic Diseases
Autoantibodies
Proteomics
Interferon-gamma
Single Nucleotide Polymorphism
Cytokines
T-Lymphocytes
Costs and Cost Analysis
Health
Therapeutics

Keywords

  • Autoantibody
  • Autoimmune disease
  • Infectious disease
  • Multiplex assays
  • Pathogen detection
  • Proteomics

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Lalvani, A., Meroni, P. L., Millington, K. A., Modolo, M. L., Plebani, M., Tincani, A., ... Ghirardello, A. (2008). Recent advances in diagnostic technology: Applications in autoimmune and infectious diseases. Clinical and Experimental Rheumatology, 26(1 SUPPL. 48).

Recent advances in diagnostic technology : Applications in autoimmune and infectious diseases. / Lalvani, Ajit; Meroni, Pier Luigi; Millington, Kerry A.; Modolo, Maria Luisa; Plebani, Mario; Tincani, Angela; Villalta, Danilo; Doria, Andrea; Ghirardello, Anna.

In: Clinical and Experimental Rheumatology, Vol. 26, No. 1 SUPPL. 48, 2008.

Research output: Contribution to journalArticle

Lalvani, A, Meroni, PL, Millington, KA, Modolo, ML, Plebani, M, Tincani, A, Villalta, D, Doria, A & Ghirardello, A 2008, 'Recent advances in diagnostic technology: Applications in autoimmune and infectious diseases', Clinical and Experimental Rheumatology, vol. 26, no. 1 SUPPL. 48.
Lalvani, Ajit ; Meroni, Pier Luigi ; Millington, Kerry A. ; Modolo, Maria Luisa ; Plebani, Mario ; Tincani, Angela ; Villalta, Danilo ; Doria, Andrea ; Ghirardello, Anna. / Recent advances in diagnostic technology : Applications in autoimmune and infectious diseases. In: Clinical and Experimental Rheumatology. 2008 ; Vol. 26, No. 1 SUPPL. 48.
@article{ee9447f93c154ecd8046c53331082635,
title = "Recent advances in diagnostic technology: Applications in autoimmune and infectious diseases",
abstract = "Biomarkers are used ubiquitously as indicators of biological health. The development of genomic and proteomic multiplex technologies have enormously amplified biomarker discovery and application to diagnostic and therapeutic decisions in clinical practice. New technologies are now available that simultaneously identify a wide spectrum of biomarkers and save time and costs. Multiplexed assays can be coupled to other disease specific indicators (i.e., cytokines, single nucleotide polymorphisms) in order to get more powerful information. However, there is an urgent need for validation/standardization of the new assays before they are adopted into clinical diagnostics. It is worthy to note a new assay, T cell interferon gamma release (TIGRAs), which has recently been introduced in the diagnosis of latent tuberculosis infection. It seems to perform better than tuberculin skin test in patients with inflammatory rheumatic diseases. In this review, we focus on advantages and limits of novel approaches to the detection of autoantibody profiles in autoimmune diseases or pathogen signatures in microbiology.",
keywords = "Autoantibody, Autoimmune disease, Infectious disease, Multiplex assays, Pathogen detection, Proteomics",
author = "Ajit Lalvani and Meroni, {Pier Luigi} and Millington, {Kerry A.} and Modolo, {Maria Luisa} and Mario Plebani and Angela Tincani and Danilo Villalta and Andrea Doria and Anna Ghirardello",
year = "2008",
language = "English",
volume = "26",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "1 SUPPL. 48",

}

TY - JOUR

T1 - Recent advances in diagnostic technology

T2 - Applications in autoimmune and infectious diseases

AU - Lalvani, Ajit

AU - Meroni, Pier Luigi

AU - Millington, Kerry A.

AU - Modolo, Maria Luisa

AU - Plebani, Mario

AU - Tincani, Angela

AU - Villalta, Danilo

AU - Doria, Andrea

AU - Ghirardello, Anna

PY - 2008

Y1 - 2008

N2 - Biomarkers are used ubiquitously as indicators of biological health. The development of genomic and proteomic multiplex technologies have enormously amplified biomarker discovery and application to diagnostic and therapeutic decisions in clinical practice. New technologies are now available that simultaneously identify a wide spectrum of biomarkers and save time and costs. Multiplexed assays can be coupled to other disease specific indicators (i.e., cytokines, single nucleotide polymorphisms) in order to get more powerful information. However, there is an urgent need for validation/standardization of the new assays before they are adopted into clinical diagnostics. It is worthy to note a new assay, T cell interferon gamma release (TIGRAs), which has recently been introduced in the diagnosis of latent tuberculosis infection. It seems to perform better than tuberculin skin test in patients with inflammatory rheumatic diseases. In this review, we focus on advantages and limits of novel approaches to the detection of autoantibody profiles in autoimmune diseases or pathogen signatures in microbiology.

AB - Biomarkers are used ubiquitously as indicators of biological health. The development of genomic and proteomic multiplex technologies have enormously amplified biomarker discovery and application to diagnostic and therapeutic decisions in clinical practice. New technologies are now available that simultaneously identify a wide spectrum of biomarkers and save time and costs. Multiplexed assays can be coupled to other disease specific indicators (i.e., cytokines, single nucleotide polymorphisms) in order to get more powerful information. However, there is an urgent need for validation/standardization of the new assays before they are adopted into clinical diagnostics. It is worthy to note a new assay, T cell interferon gamma release (TIGRAs), which has recently been introduced in the diagnosis of latent tuberculosis infection. It seems to perform better than tuberculin skin test in patients with inflammatory rheumatic diseases. In this review, we focus on advantages and limits of novel approaches to the detection of autoantibody profiles in autoimmune diseases or pathogen signatures in microbiology.

KW - Autoantibody

KW - Autoimmune disease

KW - Infectious disease

KW - Multiplex assays

KW - Pathogen detection

KW - Proteomics

UR - http://www.scopus.com/inward/record.url?scp=42549096115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42549096115&partnerID=8YFLogxK

M3 - Article

VL - 26

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 1 SUPPL. 48

ER -